ArticleThorax2012
Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality.
Article in Thorax, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 397 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
397 citing papers in PubMed, 7 syntheses or guidelines pooled it, 766 citations in OpenAlex.
- All-Cause and Cause-Specific Mortality in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis.International journal of chronic obstructive pulmonary disease · 2025Pooled it
- Remote Patient Monitoring and Machine Learning in Acute Exacerbations of Chronic Obstructive Pulmonary Disease: Dual Systematic Literature Review and Narrative Synthesis.Journal of medical Internet research · 2024Pooled it
- A systematic review and meta-analysis of chronic obstructive pulmonary disease in asia: risk factors for readmission and readmission rate.BMC pulmonary medicine · 2024Pooled it
- Frailty and its influence on mortality and morbidity in COPD: A Systematic Review and Meta-Analysis.Internal and emergency medicine · 2023Pooled it
- Effectiveness of Chinese herbal medicine combined with conventional medicine on acute exacerbation of chronic obstructive pulmonary disease: a systematic review and Meta-analysis.Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan · 2023Pooled it
- Blood biomarkers associated with acute type II respiratory failure in COPD: A meta-analysis.The clinical respiratory journal · 2022Pooled it
- Effects of oral anticoagulant therapy in patients with pulmonary diseases.Frontiers in cardiovascular medicine · 2022Pooled it
- Albuterol Digihaler in COPD Disease Management: A Real-World Study to Assess Digihaler Inhalation Parameters, Thresholds and Their Use to Identify Deterioration in Clinical Practice.International journal of chronic obstructive pulmonary disease · 2025Trial
- A tailored psychological intervention for anxiety and depression management in people with chronic obstructive pulmonary disease: TANDEM RCT and process evaluation.Health technology assessment (Winchester, England) · 2024Trial
- Development of a daily predictive model for the exacerbation of chronic obstructive pulmonary disease.Scientific reports · 2023Trial
- [Validation study of MEP questionnaire for simplified detection of exacerbation of chronic obstructive pulmonary disease].Pneumologie (Stuttgart, Germany) · 2022Trial
- Effect of pharmacist-led inhaler technique assessment service on readmissions in hospitalized COPD patients: a randomized, controlled pilot study.BMC pulmonary medicine · 2022Trial
- Efficacy of Aclidinium Bromide According to Baseline Therapy: Post-Hoc Analysis of ASCENT-COPD Randomized Trial.Advances in therapy · 2021Trial
- Long-term mortality trends of COPD and respiratory failure among adults aged ≥25 years in the United States: an analysis of CDC WONDER data (1999-2023).Annals of medicine and surgery (2012) · 2026Article
- Review
- Acute exacerbations of chronic obstructive pulmonary disease in the setting of cirrhosis: a high-risk combination.Proceedings (Baylor University. Medical Center) · 2026Article
- Real-World Dupilumab in Type 2 Chronic Obstructive Pulmonary Disease (COPD): A Single-Centre Compassionate-Use Case Series.Biomedicines · 2026Article
- Global, regional, and national trends in burden of lung cancer and chronic obstructive pulmonary disease and associated risk factors, 1990-2021: results from the global burden of disease study 2021.NPJ primary care respiratory medicine · 2026Article
- Development of an artificial intelligence prediction model for moderate-to-severe COPD exacerbations using continuous multiple unobtrusive sensors: protocol of a multicentre prospective observational study.BMJ open respiratory research · 2026Article
- Association between the Dietary Inflammatory Index and lung function in exacerbated chronic obstructive pulmonary disease: The mediating role of inflammatory indicators.Asia Pacific journal of clinical nutrition · 2026Article
337 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundThe long-term natural history of chronic obstructive pulmonary disease (COPD) in terms of successive severe exacerbations and mortality is unknown.
methodsThe authors formed an inception cohort of patients from their first ever hospitalisation for COPD during 1990-2005, using the healthcare databases from the province of Quebec, Canada. Patients were followed until death or 31 March 2007, and all COPD hospitalisations occurring during follow-up were identified. The hazard functions of successive hospitalised COPD exacerbations and all-cause mortality over time were estimated, and HRs adjusted for age, sex, calendar time and comorbidity.
resultsThe cohort included 73 106 patients hospitalised for the first time for COPD, of whom 50 580 died during the 17-year follow-up, with 50% and 75% mortality at 3.6 and 7.7 years respectively. The median time from the first to the second hospitalised exacerbation was around 5 years and decreased to <4 months from the 9th to the 10th. The risk of the subsequent severe exacerbation was increased threefold after the second severe exacerbation and 24-fold after the 10th, relative to the first. Mortality after a severe exacerbation peaked to 40 deaths per 10 000 per day in the first week after admission, dropping gradually to 5 after 3 months.
conclusionsThe course of COPD involves a rapid decline in health status after the second severe exacerbation and high mortality in the weeks following every severe exacerbation. Two strategic targets for COPD management should include delaying the second severe exacerbation and improving treatment of severe exacerbations to reduce their excessive early mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.